Increasing Medical Marijuana and Cannabidiol Research
1. Purpose
Executive Order 14370 aims to facilitate and enhance research on medical marijuana and cannabidiol (CBD) to better inform patients and healthcare providers about their risks and benefits.
2. Key Actions And Directives
- Facilitate Research: Encourage and expand medical marijuana and CBD research efforts to gather solid scientific evidence.
- Reschedule Marijuana: The Attorney General will initiate procedures to reschedule marijuana from Schedule I to Schedule III under the Controlled Substances Act.
- Improve Healthcare Conversations: Promote the importance of healthcare providers discussing marijuana use with patients to determine potential drug interactions.
3. Important Points
- Credible Medical Support: The FDA acknowledges marijuana's medical applications, supporting its rescheduling to reflect therapeutic potential.
- Wide Adoption of Medical Programs: Forty states and the District of Columbia have established regulated medical marijuana programs, highlighting public and legislative support.
- Impediments to Research: Current Schedule I classification hinders research, preventing optimal patient care and understanding of medical marijuana's effects.
- Patient-Provider Dialogue: There is a concerning gap in patient-provider discussions about marijuana use, with only 56% of older Americans reporting such conversations.
- Hemp-Derived Cannabinoids: Hemp-derived cannabinoids are defined under federal law and remain outside the CSA, subject to FDA regulations.
Disclaimer: ExecBrief's are AI generated, Please verify with the original source to confirm
Click here to provide feedback to help us improve your experience!
Comments